While mushrooms containing the psychoactive compound psilocybin remain illegal in most parts of Europe and the United States, Jamaica's government has never outlawed the hallucinogenic fungus and is now cultivating investors in efforts to build up its psychedelics industry.
Read moreKetamine and Integration
Ketamine, given through IV at clinics, has emerged as a therapy for depression. Some companies are offering an at-home version, but it's controversial.
Integration is important!
Read moreAnimals Like Psychedelics, Too!
Ibogaine for Addiction?
Supporters claim the powerfully hallucinogenic tree-bark derivative ibogaine can break the cycle of addiction and eliminate withdrawal.
Ibogaine comes from the iboga plant in Gabon, and is not legal in the US.
Read moreThe Psychedelic Renaissance Has Issues...
From New Atlas:
“Most psychedelic advocates picture a future where the drug war is over and people are free to responsibly use a number of currently illicit substances for healing, personal growth, or simple recreation. “
“But exactly how we get to that utopian future is the source of great acrimony and division in a once-unified alternative community that is increasingly moving towards the mainstream.”
Read morePsychedelics and the Brain-New Research
Psychedelic drugs may reopen critical learning periods in the brain.
Recent research shows that in adult mice, psychedelic drugs including LSD, ketamine and psilocybin have been shown to reopen the brain to a critical window for social learning usually only seen in adolescents.
Read morePsychedelics And Paralysis
Incredible story of Jim Harris, who become paralyzed from the chest down. The mountain athlete found an unlikely ally in recovery: psychedelics.
Read moreDrama and a Growing Rift in the Psychedelic Community
The psychedelic space has grown rapidly and quickly led to disagreements, attempts at profiting and patenting.
A recent psychedelic conference showed there is a widening rift in the community.
Read morePsilocybin and Antidepressants
New research suggests that antidepressants can diminish the effects of psilocybin.
Read moreRecent Research on Psilocybin Gives Mixed Results
Compass Pathways published the long awaited results of its phase 2 clinical trial for the treatment of depression with psilocybin–assisted psychotherapy in the New England Journal of Medicine.
Psilocybin showed rapid antidepressant effects for most patients, but only 1 in 5 participants showed significant improvement at 12 weeks.
Read moreMDMA and Eating Disorders
MDMA-assisted psychotherapy shows promise in the treatment of eating disorder symptoms.
Read more
Quisque iaculis facilisis lacinia. Mauris euismod pellentesque tellus sit amet mollis.